Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine and Saint Louis University Liver Center, Saint Louis, MO, USA.
Methods Mol Biol. 2024;2837:257-270. doi: 10.1007/978-1-0716-4027-2_22.
HBV is a small, enveloped DNA virus that replicates by reverse transcription of an RNA intermediate. Current anti-HBV treatment regiments employ interferon α or nucleos(t)ide analogs, but they are not curative, are of long duration, and can be accompanied by systemic side-effects. The HBV ribonuclease H (RNaseH) is essential for viral replication; however, it is unexploited as a drug target. RNaseH inhibitors that actively block viral replication would represent an important addition to the potential new drugs for treating HBV infection. Here, we describe two methods to measure the activity of RNaseH inhibitors. The DNA oligonucleotide-directed RNA cleavage assay allows mechanistic analysis of compounds for anti-HBV RNaseH activity. Analysis of preferential inhibition of plus-polarity DNA strand synthesis by HBV RNaseH inhibitors in a cell culture model of HBV replication can be used to measure the ability of RNaseH inhibitors to block viral replication.
HBV 是一种小型、包膜的 DNA 病毒,通过 RNA 中间体的逆转录进行复制。目前的抗 HBV 治疗方案采用干扰素 α 或核苷(酸)类似物,但它们不能治愈,持续时间长,并且可能伴有全身副作用。HBV 核糖核酸酶 H(RNaseH)是病毒复制所必需的,但尚未被用作药物靶点。积极阻断病毒复制的 RNaseH 抑制剂将成为治疗 HBV 感染的潜在新药的重要补充。在这里,我们描述了两种测量 RNaseH 抑制剂活性的方法。DNA 寡核苷酸指导的 RNA 切割测定允许对化合物进行抗 HBV RNaseH 活性的机制分析。在 HBV 复制的细胞培养模型中分析 HBV RNaseH 抑制剂对正链 DNA 合成的优先抑制作用,可用于测量 RNaseH 抑制剂阻断病毒复制的能力。